Last updated: November 2, 2026
Nivestym is Pfizer’s biosimilar filgrastim-aafi, approved by the FDA in 2018 for the same major indications as Neupogen, including chemotherapy-induced neutropenia, acute myeloid leukemia, severe chronic neutropenia, and hematopoietic stem-cell mobilization. Its commercial market is mature, price-sensitive, and dominated by hospital contracts, specialty distributors, group purchasing organizations, and payer formulary decisions.
Pfizer does not publicly report Nivestym revenue as a standalone product. The available financial record therefore supports directional analysis rather than a verified product-level sales trajectory. Nivestym’s economics are driven by share capture in a commoditizing filgrastim market, manufacturing scale, contracting discipline, and competition from Zarxio, Granix, Releuko, and originator Neupogen.
What is Nivestym and how does it compete in the filgrastim market?
Nivestym is a recombinant granulocyte colony-stimulating factor, or G-CSF, containing filgrastim-aafi. It is administered by subcutaneous or intravenous injection and is used to reduce the duration of neutropenia and related infection risk in specified clinical settings.
| Product |
Active ingredient |
Sponsor or manufacturer |
FDA status |
Market role |
| Nivestym |
Filgrastim-aafi |
Pfizer |
Biosimilar approved 2018 |
Pfizer’s filgrastim biosimilar |
| Neupogen |
Filgrastim |
Amgen |
Reference product |
Originator product |
| Zarxio |
Filgrastim-sndz |
Sandoz |
Biosimilar approved 2015 |
Early US biosimilar entrant |
| Granix |
Tbo-filgrastim |
Teva |
Biologic license approval |
Competing short-acting G-CSF |
| Releuko |
Filgrastim-ayow |
Amneal Pharmaceuticals |
Biosimilar approved 2022 |
Later US biosimilar entrant |
Nivestym competes primarily on net price, supply reliability, contracting access, and inclusion in institutional treatment protocols. Clinical differentiation is limited because biosimilar filgrastim products are expected to have no clinically meaningful differences from the reference product in approved uses.
When did Nivestym launch and what FDA exclusivity applies?
The FDA approved Nivestym on July 20, 2018, under the biosimilar pathway established by the Biologics Price Competition and Innovation Act. Pfizer commercialized the product after approval, with US availability beginning in 2018. The FDA designated Nivestym as biosimilar to Neupogen, not as interchangeable with Neupogen.
Nivestym did not receive a new 12-year reference-product exclusivity period. That statutory exclusivity applies to the reference biologic, not to each biosimilar. A biosimilar can enter after the applicable reference-product exclusivity and patent barriers have cleared.
| Milestone |
Date or status |
| Neupogen US approval |
1991 |
| Nivestym FDA approval |
July 20, 2018 |
| Nivestym reference product |
Neupogen |
| Approval pathway |
351(k) biosimilar |
| Separate 12-year biologic exclusivity |
No |
| Interchangeable designation |
Not listed as interchangeable in the FDA product information reviewed |
| Product-level sales disclosure |
Not separately reported by Pfizer |
The absence of a separate exclusivity period increases the importance of commercial execution. Nivestym entered a market in which the originator had already faced substantial loss of exclusivity and in which another filgrastim biosimilar, Zarxio, had reached the US market several years earlier.
What patents protect Nivestym and when do they expire?
Nivestym is not protected by the kind of new composition-of-matter patent estate typically associated with an innovative biologic. Its principal commercial protection derives from the biosimilar approval pathway, regulatory data requirements, manufacturing know-how, supply agreements, trademarks, and Pfizer’s ability to secure formulary and institutional contracts.
Neupogen’s foundational patent protection is no longer the principal barrier to filgrastim competition. The practical market question is therefore not whether Nivestym can enter, but how much share it can obtain at sustainable net pricing.
The FDA Orange Book generally does not provide the principal patent record for therapeutic biologics. Biologic patent and exclusivity information is tracked through the FDA Purple Book and related patent-disclosure mechanisms. Nivestym itself is not expected to have an Orange Book-style small-molecule patent listing that determines generic substitution.
Does Nivestym have formulation or manufacturing patent protection?
Publicly visible commercial protection for Nivestym is more likely to involve manufacturing processes, cell-line control, analytical comparability methods, formulation know-how, device or container systems, and supply-chain capabilities than a broad patent covering filgrastim itself.
These protections can matter commercially, but they usually do not prevent competing filgrastim biosimilars from reaching the market. They can increase the cost and time required for a competitor to reproduce the product consistently, satisfy regulatory comparability requirements, and maintain supply at hospital scale.
How large is the Nivestym market?
Nivestym participates in the US short-acting G-CSF market, which includes filgrastim and tbo-filgrastim products. Demand is linked to oncology treatment volume, use of myelosuppressive chemotherapy, stem-cell mobilization, acute myeloid leukemia treatment, and severe chronic neutropenia.
The market has several structural characteristics:
- Demand is clinically durable because G-CSF is embedded in chemotherapy-support protocols.
- Product differentiation is limited for routine uses.
- Purchasing is concentrated among hospitals, integrated delivery networks, oncology practices, specialty distributors, and group purchasing organizations.
- Biosimilar adoption is heavily affected by net price and supply assurance.
- Pegfilgrastim competes with short-acting filgrastim for some prophylaxis and neutropenia-management use cases.
The relevant commercial market is not defined only by unit volume. Revenue depends on dose frequency, treatment setting, product mix, channel discounts, and the shift between filgrastim and pegfilgrastim.
What is the financial trajectory of Nivestym?
Pfizer does not report Nivestym revenue, gross margin, prescription volume, or market share as separate line items in its public annual reports. Pfizer generally aggregates smaller products into broader business-unit or regional categories. As a result, no audited public series establishes Nivestym’s annual sales trajectory.
The most defensible financial interpretation is:
| Period |
Commercial trajectory |
Financial implication |
| 2018 launch |
Entry into an established biosimilar market |
Initial investment in launch, regulatory support, supply, and contracting |
| 2019-2020 |
Early formulary and hospital account expansion |
Revenue growth dependent on account wins and conversion from Neupogen or competing products |
| 2021-2022 |
Greater price competition and additional biosimilar pressure |
Unit growth could be offset by lower net price |
| 2023 onward |
Mature, contract-driven market |
More stable volume with margin pressure and limited pricing power |
Nivestym’s financial trajectory is therefore likely to be measured by contribution margin and strategic account retention rather than headline revenue growth. In a mature injectable market, a product can preserve or increase volume while generating flat or declining revenue because discounts rise faster than units.
What factors affect Nivestym profitability?
The main profitability variables are:
- Manufacturing utilization and batch scale.
- Cost of goods for recombinant protein production.
- Fill-finish and cold-chain expenses.
- Rebates and chargebacks to hospitals and distributors.
- Group purchasing organization discounts.
- Inventory losses from expiry or demand forecasting errors.
- Pricing pressure from Zarxio, Granix, Releuko, and Neupogen.
- Pfizer’s ability to bundle Nivestym with broader institutional purchasing arrangements.
- Relative use of short-acting filgrastim versus pegfilgrastim.
Nivestym’s profitability is likely stronger when Pfizer secures predictable institutional volume and weaker when it relies on broad discounting to displace established products.
Which companies are challenging Nivestym commercially?
Nivestym faces competition from both biosimilars and non-biosimilar filgrastim alternatives.
Zarxio
Zarxio, marketed by Sandoz, was the first FDA-approved biosimilar in the United States and has had a meaningful first-mover advantage. Sandoz’s experience with biosimilar contracting, physician education, and payer access gives Zarxio a significant competitive position.
Granix
Granix is tbo-filgrastim, a short-acting G-CSF approved through a biologics license application rather than the US biosimilar pathway. It competes directly for many institutional uses and can influence tender pricing even though its regulatory classification differs from Nivestym.
Releuko
Releuko added another FDA-approved filgrastim biosimilar to the US market in 2022. Its entry increases buyer leverage and raises the probability of additional rebates, lower contract prices, and account-level switching.
Neupogen
Neupogen retains brand recognition and may remain relevant where physicians, institutions, or procurement systems prefer the reference product. Its ability to maintain share depends on contracting and perceived supply or service advantages because the product faces mature biosimilar competition.
What generic-entry risks exist for Nivestym?
Nivestym does not face conventional generic substitution risk in the same way as a small-molecule drug. The principal threat is biosimilar substitution or formulary displacement.
The most important entry risks are:
- New filgrastim biosimilars offering lower net prices.
- Hospital tenders that award business to a single supplier.
- Automatic or protocol-driven conversion from one filgrastim product to another.
- Distributor inventory preferences.
- Shortages or manufacturing interruptions that shift customers between suppliers.
- Greater use of pegfilgrastim, which can reduce demand for repeated short-acting doses.
- Payer policies that favor a competing product through preferred placement.
Because Nivestym is not interchangeable under the FDA designation reviewed, pharmacy-level substitution may be more limited than for an interchangeable biosimilar. Institutional protocols and prescriber-directed switching remain central to market adoption.
What litigation and settlement issues affect Nivestym?
No major public patent-litigation event is broadly identified as the primary commercial constraint on Nivestym. The relevant legal framework is the biosimilar patent-resolution process under the Biologics Price Competition and Innovation Act, often called the patent dance.
For Nivestym, the commercial outcome has been shaped more by product launch timing, regulatory approval, contracting, and competitive pricing than by a publicly dominant patent settlement. The main litigation risks for Pfizer would involve manufacturing patents, process patents, trade secrets, supply obligations, product liability, or disputes involving competing biologics rather than a foundational patent on filgrastim.
How does Nivestym compare with Zarxio and Neupogen?
| Factor |
Nivestym |
Zarxio |
Neupogen |
| Regulatory category |
Biosimilar |
Biosimilar |
Reference biologic |
| US approval timing |
2018 |
2015 |
1991 |
| Sponsor |
Pfizer |
Sandoz |
Amgen |
| Primary advantage |
Pfizer scale and institutional access |
First-mover biosimilar position |
Brand history and reference status |
| Primary weakness |
Later entry and price pressure |
Competition from later biosimilars |
Higher exposure to biosimilar discounting |
| Product differentiation |
Limited |
Limited |
Limited for approved shared uses |
| Commercial model |
Contract and hospital driven |
Contract and hospital driven |
Brand and contract driven |
Nivestym’s position is strongest where Pfizer can convert its broader hospital relationships into reliable filgrastim volume. Its position is weaker in accounts where Zarxio has entrenched formulary status or where purchasing decisions are decided almost entirely by lowest net price.
What is the geographic coverage of Nivestym?
Nivestym is primarily analyzed as a US product because its FDA approval and Pfizer’s US commercialization are the clearest public elements of its profile. Pfizer may market related filgrastim products under different names, labels, or legal entities in other jurisdictions. Product availability, biosimilar designation, reimbursement, and patent status vary by country.
The US market has the greatest relevance for Nivestym’s reported commercial profile because of the FDA 351(k) approval, US hospital contracting structure, and Pfizer’s US product disclosures.
Key Takeaways
- Nivestym is Pfizer’s FDA-approved filgrastim-aafi biosimilar, launched in 2018.
- Pfizer does not separately disclose Nivestym revenue, units, profit, or market share.
- The product operates in a mature, highly price-sensitive G-CSF market.
- Zarxio, Granix, Releuko, and Neupogen are the principal commercial comparators.
- Nivestym has no separate 12-year biologic exclusivity period.
- The main commercial protections are manufacturing capability, regulatory compliance, supply reliability, contracting, and institutional access.
- Revenue can remain stable or decline even if volume grows because biosimilar rebates and hospital discounts reduce net price.
- No major public patent dispute appears to be the principal constraint on Nivestym’s market performance.
- Future value depends on Pfizer’s ability to retain hospital contracts, control manufacturing costs, and defend share against additional filgrastim competition.
FAQs About Nivestym Market Performance
Does Pfizer disclose annual Nivestym sales?
No. Pfizer does not publicly report Nivestym as a standalone revenue line in its principal financial disclosures.
Is Nivestym interchangeable with Neupogen?
Nivestym is FDA-approved as a biosimilar to Neupogen. The product information reviewed does not identify an interchangeable designation, so substitution rules depend on state law, institutional policy, payer requirements, and prescriber direction.
Is Nivestym listed in the Orange Book?
Biologic patent and exclusivity analysis is generally conducted through the FDA Purple Book and applicable biologic patent-disclosure procedures rather than the Orange Book framework used for small-molecule drugs.
What is the biggest commercial threat to Nivestym?
The largest threat is intensified biosimilar and short-acting G-CSF price competition, particularly from Zarxio, Releuko, Granix, and any additional entrants that win hospital tenders through lower net pricing.
Does Nivestym face biosimilar competition despite being a biosimilar?
Yes. Biosimilars compete directly with other biosimilars. Nivestym’s market position depends on contracting, supply, manufacturing cost, and institutional access rather than regulatory exclusivity.
References
- Amgen Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Food and Drug Administration. (2018, July 20). FDA approves new biosimilar product, Nivestym. U.S. Department of Health and Human Services.
- Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
- Food and Drug Administration. (2024). Nivestym (filgrastim-aafi) prescribing information. U.S. Department of Health and Human Services.
- Pfizer Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Sandoz Group AG. (2024). Annual report 2023.
- U.S. Congress. (2010). Patient Protection and Affordable Care Act, Biologics Price Competition and Innovation Act provisions.